Drug intelligence / Profile preview

anti-pseudomonas aeruginosa bacteriophage cocktail PP1131

Development stage: Discontinued
Lead developer: PHAXIAM Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

PP1131 is an investigational biologic therapy consisting of a cocktail of 12 natural lytic bacteriophages developed by Phaxiam Therapeutics (formerly Pherecydes Pharma). It is designed to treat burn wound infections by specifically targeting and destroying *Pseudomonas aeruginosa* bacteria. The therapy was evaluated in the Phase I/II PhagoBurn clinical trial (NCT02116010), where it was administered topically. The trial was stopped in January 2017 due to insufficient efficacy compared to the standard of care (1% silver sulfadiazine cream). This was attributed to the administration of a much lower phage concentration (1 × 10^2 PFU/mL) than intended due to titre loss after manufacturing. Despite the trial's outcome, researchers concluded that further studies with increased phage concentrations would be warranted.

Targets

P. aeruginosa (Pseudomonas aeruginosa)Pseudomonas aeruginosa cell-surface phage receptors

Beyond the preview

Go deeper on anti-pseudomonas aeruginosa bacteriophage cocktail PP1131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-pseudomonas aeruginosa bacteriophage cocktail PP1131.

Explore the full profile